Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma

Resistance to targeted therapy is an ongoing problem for the successful treatment of Stage IV metastatic melanoma. For many patients, the use of targeted therapies, such as BRAF kinase inhibitors, were initially promising yet resistance inevitably occurred. Even after combining BRAF kinase inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Keller, Hilary R., Zhang, Xin, Li, Li, Schaider, Helmut, Wells, James W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650456/
https://www.ncbi.nlm.nih.gov/pubmed/29088901
http://dx.doi.org/10.18632/oncotarget.18523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650456/
https://www.ncbi.nlm.nih.gov/pubmed/29088901
http://dx.doi.org/10.18632/oncotarget.18523

Ejemplares similares